UK, (England), Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study
https://www.bmj.com/content/374/bmj.n1931
https://www.bbc.co.uk/news/health-58347434
Prof Julia Hippisley-Cox
People vaccinated with first doses, 16 or over
N = 29,121,633
Oxford-AstraZeneca (ChAdOx1 nCoV-19)
N = 19,608,008
Pfizer-BioNTech (BNT162b2mRNA)
N = 9,513,625
People testing positive SARSCoV-2
N = 1,758,095
Within 28 days of three exposures
First dose of the ChAdOx1 nCoV-19 vaccine
First dose of the BNT162b2 mRNA vaccine
SARS-CoV-2 positive test
For every 10 million people vaccinated with the AstraZeneca
An extra 107 would be hospitalised or die from thrombocytopenia
(1 in 93,459)
9 times lower than the risk following an infection
An extra 66 would be hospitalised or die from blood clots in the veins
Nearly 200 times lower than the risk following an infection
For every 10 million people vaccinated with the Pfizer
An extra 143 extra strokes would be seen
(1 in 69,930)
12 times lower than the risk following an infection
Myocarditis and pericarditis
Chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021
https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm
52 million doses to 12–29 years
1,226 reports of myocarditis after mRNA vaccination 42,414
One in 42,414
Data demonstrate increased risks, particularly within the seven days following the second dose
The observed risk is higher among males under 40 years of age compared to females and older males
Risk is highest in males 12 through 17 years of age
Source